FDA Expands Use of Toujeo to Childhood Type 1 Diabetes FDA Expands Use of Toujeo to Childhood Type 1 Diabetes
First approved for US adults with type 1 and type 2 diabetes in 2015, Toujeo (insulin glargine 300 units/mL injection) may now be used in children as young as 6 years with type 1 diabetes.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Children | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | Lantus